Literature DB >> 17430244

Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics.

Guoqing Cao1, Kelly R Bales, Ronald B DeMattos, Steven M Paul.   

Abstract

Liver X receptors (LXRalpha and LXRbeta) are oxysterol receptors that function as master transcription factors mediating cholesterol homeostasis in the periphery. LXRs regulate the levels of the ABCA1 and ABCG1 cholesterol transporters as well as apolipoproteins (apoE and apoC) in various cells thereby affecting cholesterol transport and metabolism. In the brain, LXRs regulate ABCA1 in both neurons and glia resulting in cholesterol efflux from these cells. In addition, the expression of apolipoprotein E (apoE), synthesized primarily by astrocytes and microglia, is also upregulated by LXR agonists. As both apoE and the ABCA1 transporter are intimately involved in amyloid-beta peptide (Abeta) transport and clearance, activation of these genes by LXR agonists in brain may have a significant impact on Abeta deposition and amyloid/neuritic plaque formation. Furthermore, LXR activation has been shown to have significant anti-inflammatory properties. Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430244     DOI: 10.2174/156720507780362173

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  23 in total

Review 1.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

2.  Hydroxysteroid sulfotransferase 2B1b expression and localization in normal human brain.

Authors:  Emily D Salman; Ona Faye-Petersen; Charles N Falany
Journal:  Horm Mol Biol Clin Investig       Date:  2011-10

3.  Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment.

Authors:  Inga Kadish; Olivier Thibault; Eric M Blalock; Kuey-C Chen; John C Gant; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 4.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

Review 5.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

6.  Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner.

Authors:  Lance A Johnson; Reid H J Olsen; Louise S Merkens; Andrea DeBarber; Robert D Steiner; Patrick M Sullivan; Nobuyo Maeda; Jacob Raber
Journal:  Neurobiol Dis       Date:  2014-01-09       Impact factor: 5.996

Review 7.  APOE in the normal brain.

Authors:  Sarah A Flowers; G William Rebeck
Journal:  Neurobiol Dis       Date:  2020-01-03       Impact factor: 5.996

Review 8.  Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering.

Authors:  Irina A Pikuleva
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-11       Impact factor: 4.481

9.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats.

Authors:  Sokreine Suon; Jie Zhao; Stephanie A Villarreal; Nikesh Anumula; Mali Liu; Linda M Carangia; John J Renger; Celina V Zerbinatti
Journal:  Mol Neurodegener       Date:  2010-10-29       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.